• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Safety

  • Print
  • Share
  • E-mail

Tyzeka (telbivudine) tablets and oral solution

Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER) 

 

January 2013

Summary View

6 ADVERSE REACTIONS

6.1 Clinical Trial Experience

Results at 208 Weeks

  • update with the long-term safety and efficacy data from Study CLDT600A2303 for subjects previously enrolled in the original two year GLOBE (NV-02B-007/CLDT600A2302) and NV02B-015 studies who  continued telbivudine treatment for up to 208 weeks

12 CLINICAL PHARMACOLOGY

NOTE:  updated data also added to section 12

 

December 2011 

Summary View

 

CONTRAINDICATIONS

  • Combination of Tyzeka with pegylated interferon alfa-2a is contraindicated because of increased risk of peripheral neuropathy.

 

WARNINGS AND PRECAUTIONS

Peripheral Neuropathy

  • Peripheral neuropathy has been reported with Tyzeka alone or in combination with pegylated interferon alfa-2a and other interferons. In one clinical trial, an increased risk and severity of peripheral neuropathy was observed with the combination use of Tyzeka 600mg daily and pegylated interferon alfa-2a 180 micrograms once weekly compared to Tyzeka or pegylated interferon alfa-2a alone. Such risk cannot be excluded for other dose regimens of pegylated interferon alfa-2a, or other alfa interferons (pegylated or standard). The safety and efficacy of Tyzeka in combination with pegylated interferons or other interferons for the treatment of chronic hepatitis B has not been demonstrated. Patients should be advised to report any numbness, tingling, and/or burning sensations in the arms and/or legs, with or without gait disturbance. Tyzeka therapy should be interrupted if peripheral neuropathy is suspected, and discontinued if peripheral neuropathy is confirmed.

 

DRUG INTERACTIONS

  • A clinical trial investigating the combination of Tyzeka, 600 mg daily, with pegylated interferon alfa-2a, 180 micrograms once weekly by subcutaneous administration, indicates that this combination is associated with an increased risk of peripheral neuropathy occurrence and severity, in comparison to Tyzeka or pegylated interferon alfa-2a alone.